BidaskClub Downgrades Flexion Therapeutics (FLXN) to Strong Sell

BidaskClub cut shares of Flexion Therapeutics (NASDAQ:FLXN) from a sell rating to a strong sell rating in a research report report published on Saturday morning.

Several other brokerages have also recently issued reports on FLXN. Wells Fargo & Co set a $39.00 price objective on shares of Flexion Therapeutics and gave the company a buy rating in a research note on Monday, October 30th. Zacks Investment Research lowered shares of Flexion Therapeutics from a hold rating to a sell rating in a report on Tuesday, October 17th. Needham & Company LLC boosted their target price on shares of Flexion Therapeutics from $36.00 to $42.00 and gave the company a buy rating in a report on Monday, October 9th. Northland Securities reiterated a buy rating and issued a $40.00 target price on shares of Flexion Therapeutics in a report on Wednesday, October 4th. Finally, ValuEngine upgraded shares of Flexion Therapeutics from a sell rating to a hold rating in a report on Sunday, December 31st. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have given a buy rating to the stock. Flexion Therapeutics presently has a consensus rating of Buy and a consensus target price of $106.25.

Flexion Therapeutics (FLXN) traded up $0.74 during mid-day trading on Friday, hitting $23.41. 714,778 shares of the stock were exchanged, compared to its average volume of 918,641. The stock has a market capitalization of $878.83, a PE ratio of -6.65 and a beta of 1.14. The company has a quick ratio of 12.93, a current ratio of 12.93 and a debt-to-equity ratio of 0.87. Flexion Therapeutics has a twelve month low of $16.51 and a twelve month high of $32.25.

Flexion Therapeutics (NASDAQ:FLXN) last announced its quarterly earnings data on Monday, November 6th. The specialty pharmaceutical company reported ($1.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.98) by ($0.09). equities research analysts expect that Flexion Therapeutics will post -3.84 earnings per share for the current year.

In other Flexion Therapeutics news, insider Michael D. Clayman bought 5,000 shares of Flexion Therapeutics stock in a transaction on Wednesday, November 8th. The shares were bought at an average cost of $23.60 per share, for a total transaction of $118,000.00. Following the acquisition, the insider now directly owns 35,395 shares in the company, valued at $835,322. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Neil Bodick bought 2,700 shares of Flexion Therapeutics stock in a transaction on Tuesday, November 21st. The shares were acquired at an average price of $24.49 per share, for a total transaction of $66,123.00. Following the completion of the acquisition, the insider now owns 64,605 shares in the company, valued at $1,582,176.45. The disclosure for this purchase can be found here. 15.98% of the stock is owned by corporate insiders.

Several large investors have recently made changes to their positions in the business. Macquarie Group Ltd. increased its position in shares of Flexion Therapeutics by 0.6% in the 2nd quarter. Macquarie Group Ltd. now owns 55,917 shares of the specialty pharmaceutical company’s stock valued at $1,131,000 after purchasing an additional 338 shares during the last quarter. Schwab Charles Investment Management Inc. increased its position in shares of Flexion Therapeutics by 0.5% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 101,214 shares of the specialty pharmaceutical company’s stock valued at $2,047,000 after purchasing an additional 513 shares during the last quarter. The Manufacturers Life Insurance Company increased its position in shares of Flexion Therapeutics by 3.9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 21,802 shares of the specialty pharmaceutical company’s stock valued at $441,000 after purchasing an additional 811 shares during the last quarter. ProShare Advisors LLC increased its position in shares of Flexion Therapeutics by 5.5% in the 2nd quarter. ProShare Advisors LLC now owns 18,750 shares of the specialty pharmaceutical company’s stock valued at $379,000 after purchasing an additional 982 shares during the last quarter. Finally, Cadence Capital Management LLC increased its position in shares of Flexion Therapeutics by 5.1% in the 3rd quarter. Cadence Capital Management LLC now owns 54,002 shares of the specialty pharmaceutical company’s stock valued at $1,306,000 after purchasing an additional 2,612 shares during the last quarter. 72.78% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This piece of content was posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark law. The original version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3149168/bidaskclub-downgrades-flexion-therapeutics-flxn-to-strong-sell.html.

Flexion Therapeutics Company Profile

Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.

Analyst Recommendations for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.